New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:08 EDTGSK, EPZMEpizyme earns 2M milestone payment from GlaxoSmithKline
Epizyme (EPZM) achieved the lead candidate selection milestone for one of the histone methyltransferase targets in the company's collaboration with GlaxoSmithKline (GSK). This achievement triggers a milestone payment of $2M.
News For EPZM;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:38 EDTEPZMEpizyme update for EPZ-6438 encouraging, says Mizuho
Subscribe for More Information
06:33 EDTEPZMEpizyme to host conference call
Conference call to discuss results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 will be held on November 20 at 8 am. Webcast Link
November 19, 2014
18:06 EDTEPZMEpizyme reports results from Phase 1 dose study of EZH2 inhibitor EPZ-6438
Subscribe for More Information
07:52 EDTGSKInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
07:20 EDTEPZM, GSKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 17, 2014
17:02 EDTGSKClovis in oncology clinical trial collaboration with GlaxoSmithKline
Subscribe for More Information
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
November 14, 2014
14:53 EDTGSKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTGSKAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
12:59 EDTGSKApollo plans bid for GSK mature drugs business, Reuters reports
Subscribe for More Information
November 12, 2014
12:24 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
09:16 EDTGSKLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:53 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
After GlaxoSmithKline cut its near-term EPS guidance, Argus still believes that the company's deals with Novartis (NVS) should boost its EPS growth in the years ahead, likely as soon as 2015. The firm thinks the stock is a good value for long-term investors, and it keeps a Buy rating on the shares.
08:18 EDTGSKUBS to hold a conference
Subscribe for More Information
November 10, 2014
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
November 6, 2014
07:41 EDTEPZMEpizyme announces publication of EPZ-5676 Phase 1 study
Subscribe for More Information
07:40 EDTEPZMEpizyme sees FY14 research, development expenses $75M
Epizyme continues to expect general and administrative expenses in FY14 to be approximately $20M, including non-cash expenses of approximately $3.5M. Epizyme expects to end fY14 with more than $170M in cash and cash equivalents. The company expects that these funds, together with expected research funding under the company’s collaborations, will fund the company until at least mid-2016 prior to including any potential future milestone payments.
07:39 EDTEPZMEpizyme backs FY14 guidance
Subscribe for More Information
07:38 EDTEPZMEpizyme reports Q3 EPS (58c), consensus (55c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use